

David Capper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8112466/publications.pdf>

Version: 2024-02-01

268
papers

30,590
citations

5268

83
h-index

5394

164
g-index

279
all docs

279
docs citations

279
times ranked

27814
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
2	A complex secretory program orchestrated by the inflammasome controls paracrine senescence. <i>Nature Cell Biology</i> , 2013, 15, 978-990.	10.3	1,566
3	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. <i>Acta Neuropathologica</i> , 2009, 118, 469-474.	7.7	1,020
4	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	16.8	933
5	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 397-405.	7.7	914
6	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	27.8	787
7	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. <i>Acta Neuropathologica</i> , 2010, 120, 707-718.	7.7	719
8	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
9	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	27.8	637
10	<scp>WHO</scp> 2016 Classification of gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 139-150.	3.2	612
11	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	10.7	586
12	Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. <i>Brain Pathology</i> , 2010, 20, 245-254.	4.1	463
13	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. <i>Acta Neuropathologica</i> , 2011, 122, 11-19.	7.7	445
14	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	16.8	438
15	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2016, 17, 1521-1532.	10.7	396
16	Monoclonal antibody specific for IDH1 R132H mutation. <i>Acta Neuropathologica</i> , 2009, 118, 599-601.	7.7	380
17	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015, 129, 133-146.	7.7	378
18	cIMPACT-Now update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	4.1	363

#	ARTICLE	IF	CITATIONS
19	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. <i>Acta Neuropathologica</i> , 2013, 125, 651-658.	7.7	324
20	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. <i>Acta Neuropathologica</i> , 2018, 136, 181-210.	7.7	308
21	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. <i>Acta Neuropathologica</i> , 2013, 126, 443-451.	7.7	304
22	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166.	7.7	298
23	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65.	3.7	289
24	TERT Promoter Mutations and Risk of Recurrence in Meningioma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv377.	6.3	283
25	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. <i>Acta Neuropathologica</i> , 2018, 135, 639-642.	7.7	281
26	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. <i>Acta Neuropathologica</i> , 2015, 129, 669-678.	7.7	277
27	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. <i>Acta Neuropathologica</i> , 2015, 129, 867-873.	7.7	272
28	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. <i>Acta Neuropathologica</i> , 2014, 128, 551-559.	7.7	268
29	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	2.8	262
30	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. <i>Acta Neuropathologica</i> , 2009, 118, 401-405.	7.7	255
31	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013, 126, 907-915.	7.7	254
32	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , 2015, 130, 407-417.	7.7	237
33	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	12.8	237
34	Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. <i>Radiology</i> , 2016, 281, 907-918.	7.3	236
35	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. <i>Acta Neuropathologica</i> , 2013, 125, 351-358.	7.7	208
36	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. <i>Acta Neuropathologica</i> , 2012, 123, 223-233.	7.7	204

#	ARTICLE	IF	CITATIONS
37	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910.	7.7	203
38	Targeting the BRAF V600E Mutation in Multiple Myeloma. <i>Cancer Discovery</i> , 2013, 3, 862-869.	9.4	202
39	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. <i>Blood</i> , 2012, 120, e28-e34.	1.4	199
40	Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. <i>Molecular Therapy</i> , 2017, 25, 2620-2634.	8.2	199
41	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1146-1156.	1.2	197
42	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 793-803.	7.7	195
43	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , 2018, 136, 273-291.	7.7	190
44	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. <i>Nature Medicine</i> , 2016, 22, 1314-1320.	30.7	183
45	Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 844-850.	3.7	177
46	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. <i>Acta Neuropathologica</i> , 2013, 125, 891-900.	7.7	177
47	p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer. <i>Cell</i> , 2014, 158, 579-592.	28.9	176
48	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014, 128, 561-571.	7.7	176
49	Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. <i>Acta Neuropathologica</i> , 2017, 133, 417-429.	7.7	172
50	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 848-857.	1.2	170
51	cIMPACTâ€œNOW update 7: advancing the molecular classification of ependymal tumors. <i>Brain Pathology</i> , 2020, 30, 863-866.	4.1	168
52	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	7.7	163
53	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. <i>Acta Neuropathologica</i> , 2016, 131, 137-146.	7.7	162
54	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157

#	ARTICLE	IF	CITATIONS
55	Methylation-based classification of benign and malignant peripheral nerve sheath tumors. <i>Acta Neuropathologica</i> , 2016, 131, 877-887.	7.7	151
56	Addressing Diffuse Glioma as a Systemic Brain Disease With Single-Cell Analysis. <i>Archives of Neurology</i> , 2012, 69, 523.	4.5	148
57	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. <i>Acta Neuropathologica</i> , 2017, 133, 629-644.	7.7	146
58	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). <i>Acta Neuropathologica</i> , 2018, 135, 481-484.	7.7	145
59	Detection of BRAF p.V600E Mutations in Melanomas. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 94-100.	2.8	144
60	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. <i>Acta Neuropathologica</i> , 2017, 134, 507-516.	7.7	144
61	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. <i>Cancer Cell</i> , 2018, 33, 829-842.e5.	16.8	140
62	Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. <i>Acta Neuropathologica Communications</i> , 2016, 4, 20.	5.2	136
63	Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1796-1800.	3.7	135
64	<scp>BRAF V600E</scp> Mutation Is Associated with <scp>mTOR</scp> Signaling Activation in Glioneuronal Tumors. <i>Brain Pathology</i> , 2014, 24, 52-66.	4.1	129
65	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. <i>Acta Neuropathologica</i> , 2016, 132, 149-151.	7.7	127
66	BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1592-1602.	3.7	125
67	Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. <i>Acta Neuropathologica</i> , 2011, 121, 241-252.	7.7	124
68	Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. <i>Journal of Neuroscience Research</i> , 2007, 85, 1336-1346.	2.9	120
69	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017, 133, 1-3.	7.7	120
70	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. <i>Acta Neuropathologica</i> , 2018, 136, 239-253.	7.7	118
71	Low-grade epilepsy-associated neuroepithelial tumours – the 2016 WHO classification. <i>Nature Reviews Neurology</i> , 2016, 12, 732-740.	10.1	113
72	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. <i>EMBO Journal</i> , 2012, 31, 2629-2647.	7.8	110

#	ARTICLE	IF	CITATIONS
73	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	9.4	110
74	Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1199-1204.	3.7	108
75	Diagnostic value of immunohistochemistry for the detection of the BRAF mutation in primary lung adenocarcinoma Caucasian patients. <i>Annals of Oncology</i> , 2013, 24, 742-748.	1.2	103
76	Nuclear relocation of STAT6 reliably predicts NAB2-STAT6 fusion for the diagnosis of solitary fibrous tumour. <i>Histopathology</i> , 2014, 65, 613-622.	2.9	101
77	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. <i>Acta Neuropathologica Communications</i> , 2019, 7, 24.	5.2	101
78	Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	100
79	BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. <i>Modern Pathology</i> , 2014, 27, 1028-1034.	5.5	96
80	BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. <i>International Journal of Cancer</i> , 2013, 133, 1624-1630.	5.1	93
81	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. <i>Brain Pathology</i> , 2018, 28, 656-662.	4.1	89
82	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. <i>Nature Protocols</i> , 2020, 15, 479-512.	12.0	89
83	Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. <i>Acta Neuropathologica</i> , 2009, 117, 445-456.	7.7	88
84	AKT1E17K mutations cluster with meningotheial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. <i>Acta Neuropathologica</i> , 2013, 126, 757-762.	7.7	88
85	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. <i>Acta Neuropathologica</i> , 2020, 139, 193-209.	7.7	83
86	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. <i>Neuro-Oncology</i> , 2013, 15, 1017-1026.	1.2	78
87	Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. <i>Human Pathology</i> , 2013, 44, 329-335.	2.0	77
88	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014, 16, 1630-1638.	1.2	77
89	Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. <i>International Journal of Cancer</i> , 2012, 131, 766-768.	5.1	74
90	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. <i>Acta Neuropathologica</i> , 2015, 130, 419-434.	7.7	74

#	ARTICLE	IF	CITATIONS
91	Gliomatosis cerebri: no evidence for a separate brain tumor entity. <i>Acta Neuropathologica</i> , 2016, 131, 309-319.	7.7	74
92	Evidence of H3 K27M mutations in posterior fossa ependymomas. <i>Acta Neuropathologica</i> , 2016, 132, 635-637.	7.7	73
93	<i>BRAF</i> Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and <i>CD34</i> Expression. <i>Brain Pathology</i> , 2014, 24, 221-229.	4.1	72
94	Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. <i>Investigational New Drugs</i> , 2020, 38, 1570-1579.	2.6	70
95	Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. <i>Neuro-Oncology</i> , 2014, 16, 914-923.	1.2	69
96	Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. <i>Acta Neuropathologica</i> , 2008, 115, 249-259.	7.7	68
97	Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in <i>BRAF</i> and <i>TERT</i> . <i>Endocrine-Related Cancer</i> , 2015, 22, 419-429.	3.1	68
98	Integrated molecular characterization of <i>IDH1</i> mutant glioblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 108-118.	3.2	68
99	Response to trametinib treatment in progressive pediatric low-grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2020, 149, 499-510.	2.9	68
100	Continued Response Off Treatment After <i>BRAF</i> Inhibition in Refractory Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, e300-e303.	1.6	67
101	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. <i>Neuro-Oncology</i> , 2016, 18, 790-796.	1.2	67
102	No prognostic value of <i>IDH1</i> mutations in a series of 100 WHO grade II astrocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 15-22.	2.9	66
103	Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles. <i>Brain Pathology</i> , 2015, 25, 202-208.	4.1	66
104	Utilization of a MAB for <i>BRAFV600E</i> detection in papillary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2012, 19, 779-784.	3.1	65
105	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. <i>Annals of Oncology</i> , 2018, 29, 1423-1430.	1.2	65
106	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. <i>Neuro-Oncology</i> , 2018, 20, 1616-1624.	1.2	65
107	<i>YAP1</i> subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. <i>Nature Communications</i> , 2019, 10, 3914.	12.8	65
108	Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. <i>Brain Pathology</i> , 2016, 26, 517-522.	4.1	63

#	ARTICLE	IF	CITATIONS
109	cIMPACTâ€œNOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 27, 851-852.	4.1	63
110	Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1416-1425.	4.9	62
111	Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 661-672.	2.8	61
112	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	7.7	59
113	PCRâ€œand Restriction Endonucleaseâ€œBased Detection of <i>IDH1</i> Mutations. Brain Pathology, 2010, 20, 298-300.	4.1	58
114	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1â€œdeficient nonâ€œrhabdoid tumor with favorable longâ€œterm outcome. Brain Pathology, 2017, 27, 411-418.	4.1	58
115	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Childrenâ€œs Oncology Group Randomized ACNS0332 Trial. Journal of Clinical Oncology, 2018, 36, 3388-3395.	1.6	58
116	Detection of<i>BRAF</i>p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Archives of Pathology and Laboratory Medicine, 2014, 138, 71-75.	2.5	57
117	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro-Oncology, 2014, 16, 92-102.	1.2	57
118	Diagnostic Value of Immunohistochemistry for the Detection of the <i>BRAF</i>V600E</sup></i> Mutation in Papillary Thyroid Carcinoma: Comparative Analysis with Three DNA-Based Assays. Thyroid, 2014, 24, 858-866.	4.5	57
119	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathologica, 2019, 138, 497-504.	7.7	57
120	Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. Journal of Neuroimmunology, 2007, 189, 50-58.	2.3	56
121	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. British Journal of Cancer, 2013, 108, 924-931.	6.4	55
122	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Brain Pathology, 2019, 29, 325-335.	4.1	55
123	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	7.0	55
124	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. The Lancet Child and Adolescent Health, 2020, 4, 121-130.	5.6	55
125	IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. , 2011, 30, 217-230.		55
126	<i>GRHL1</i> Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. Cancer Research, 2014, 74, 2604-2616.	0.9	54

#	ARTICLE	IF	CITATIONS
127	Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. <i>Nature Communications</i> , 2018, 9, 2868.	12.8	54
128	Modulation of TGF α activity by latent TGF α -binding protein 1 in human malignant glioma cells. <i>International Journal of Cancer</i> , 2009, 125, 530-540.	5.1	53
129	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. <i>Modern Pathology</i> , 2013, 26, 1255-1263.	5.5	52
130	Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 488-491.	1.2	51
131	BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the Cerebellum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 867-872.	1.7	51
132	Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. <i>BMC Cancer</i> , 2016, 16, 81.	2.6	51
133	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. <i>Clinical Sarcoma Research</i> , 2017, 7, 9.	2.3	51
134	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an <i>In Vivo</i> Model of Childhood Astrocytoma. <i>Clinical Cancer Research</i> , 2013, 19, 6716-6729.	7.0	50
135	BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 733-742.	3.2	50
136	Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry. <i>Brain Pathology</i> , 2012, 22, 26-31.	4.1	49
137	Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. <i>Modern Pathology</i> , 2014, 27, 135-144.	5.5	49
138	Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. <i>Journal of Neurochemistry</i> , 2014, 131, 251-264.	3.9	47
139	Review: Challenges in the histopathological classification of ganglioglioma and DNT: microscopic agreement studies and a preliminary genotype-phenotype analysis. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 95-107.	3.2	46
140	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. <i>Oncology Reports</i> , 2017, 38, 3291-3296.	2.6	46
141	A pan-tissue DNA methylation atlas enables in silico decomposition of human tissue methylomes at cell-type resolution. <i>Nature Methods</i> , 2022, 19, 296-306.	19.0	46
142	Infratentorial IDH-mutant astrocytoma is a distinct subtype. <i>Acta Neuropathologica</i> , 2020, 140, 569-581.	7.7	45
143	Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup. <i>American Journal of Surgical Pathology</i> , 2018, 42, 506-511.	3.7	43
144	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. <i>Acta Neuropathologica</i> , 2019, 137, 837-846.	7.7	43

#	ARTICLE	IF	CITATIONS
145	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. <i>Oncotarget</i> , 2017, 8, 11460-11479.	1.8	43
146	Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma. <i>PLoS ONE</i> , 2014, 9, e86194.	2.5	42
147	Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. <i>Acta Neuropathologica</i> , 2014, 127, 565-572.	7.7	41
148	Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 205-216.	3.2	41
149	Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. <i>Seminars in Cancer Biology</i> , 2022, 84, 129-143.	9.6	41
150	Increased levels of 2-hydroxyglutarate in AML patients with IDH1 R132H and IDH2 R140Q mutations. <i>European Journal of Haematology</i> , 2010, 85, 457-459.	2.2	39
151	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. <i>Brain Pathology</i> , 2016, 26, 199-205.	4.1	39
152	Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. <i>Molecular Cancer Research</i> , 2018, 16, 1491-1498.	3.4	39
153	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion – Positive Supratentorial Ependymomas. <i>Cancer Discovery</i> , 2021, 11, 2230-2247.	9.4	39
154	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. <i>Neuropathology</i> , 2015, 35, 538-544.	1.2	38
155	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , 2019, 7, 163.	5.2	37
156	Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. <i>Neuro-Oncology</i> , 2018, 20, 1517-1524.	1.2	36
157	DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer. <i>Modern Pathology</i> , 2019, 32, 855-865.	5.5	36
158	Pediatric atypical choroid plexus papilloma reconsidered: increased mitotic activity is prognostic only in older children. <i>Acta Neuropathologica</i> , 2015, 129, 925-927.	7.7	35
159	High-grade astrocytoma with piloid features (HGAP): the CharitÄ© experience with a new central nervous system tumor entity. <i>Journal of Neuro-Oncology</i> , 2021, 153, 109-120.	2.9	35
160	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. <i>Journal of Clinical Investigation</i> , 2015, 125, 593-606.	8.2	35
161	Somatic mutations of <i>DICER1</i> and <i>KMT2D</i> are frequent in intraocular medulloepitheliomas. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 418-427.	2.8	34
162	Invited Review: DNA methylation-based classification of paediatric brain tumours. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 28-47.	3.2	33

#	ARTICLE	IF	CITATIONS
163	Recurrent fusions in <i>PLAGL1</i> define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839.	7.7	33
164	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995.	4.1	32
165	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study. <i>Neuro-Oncology</i> , 2018, 20, 826-837.	1.2	32
166	Rathke's cleft cyst rupture as potential initial event of a secondary perifocal lymphocytic hypophysitis: proposal of an unusual pathogenetic event and review of the literature. <i>Neurosurgical Review</i> , 2008, 31, 157-163.	2.4	31
167	Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. <i>BMC Medicine</i> , 2016, 14, 170.	5.5	31
168	The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signalling. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 687-706.	3.2	31
169	DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. <i>Neuro-Oncology</i> , 2021, 23, 240-250.	1.2	31
170	Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1131-1137.	2.5	30
171	VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. <i>Acta Neuropathologica</i> , 2013, 125, 911-912.	7.7	28
172	Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 159-164.	1.2	27
173	Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 358-365.	1.7	27
174	IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1190-1204.	3.7	26
175	Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. <i>Journal of Neuro-Oncology</i> , 2016, 129, 319-328.	2.9	25
176	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. <i>Cancers</i> , 2019, 11, 122.	3.7	25
177	Management of pineal region tumors in a pediatric case series. <i>Neurosurgical Review</i> , 2021, 44, 1417-1427.	2.4	25
178	Diagnostic value of WT1 in neuroepithelial tumours. <i>Neuropathology and Applied Neurobiology</i> , 2009, 35, 69-81.	3.2	24
179	<i>EGR1</i> is Regulated by N-Methyl-D-Aspartate Receptor Stimulation and Associated with Patient Survival in Human High Grade Astrocytomas. <i>Brain Pathology</i> , 2009, 19, 195-204.	4.1	24
180	Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab149.	0.7	23

#	ARTICLE	IF	CITATIONS
181	Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. <i>Acta Neuropathologica</i> , 2019, 138, 331-334.	7.7	22
182	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	1.2	22
183	Chromogenic <i>in situ</i> Hybridization is a Reliable Alternative to Fluorescence <i>in situ</i> Hybridization for Diagnostic Testing of 1p and 19q Loss in Paraffin-Embedded Gliomas. <i>Brain Pathology</i> , 2013, 23, 311-318.	4.1	21
184	Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. <i>Oncotarget</i> , 2015, 6, 13579-13590.	1.8	21
185	Risk factors for glioblastoma therapy associated complications. <i>Clinical Neurology and Neurosurgery</i> , 2015, 134, 55-59.	1.4	21
186	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. <i>Clinical Epigenetics</i> , 2019, 11, 117.	4.1	21
187	Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. <i>Acta Neuropathologica</i> , 2020, 140, 893-906.	7.7	19
188	Machine learning models predict the primary sites of head and neck squamous cell carcinoma metastases based on <i>scp</i> DNA <i>scp</i> methylation. <i>Journal of Pathology</i> , 2022, 256, 378-387.	4.5	19
189	Atypical Type II Silent Corticotrophic Adenoma Developing into Cushing's Disease upon Second Recurrence. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, 610-615.	1.2	18
190	De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 299-307.	3.2	18
191	Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. <i>Leukemia Research</i> , 2010, 34, 1091-1093.	0.8	18
192	<i>LOC283731</i> promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. <i>International Journal of Cancer</i> , 2016, 139, 424-432.	5.1	18
193	Synchronous pituitary adenoma and pituicytoma. <i>Human Pathology</i> , 2016, 47, 138-143.	2.0	18
194	Oligosarcomas, IDH-mutant are distinct and aggressive. <i>Acta Neuropathologica</i> , 2022, 143, 263-281.	7.7	18
195	Secondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy. <i>American Journal of Emergency Medicine</i> , 2014, 32, 947.e3-947.e5.	1.6	17
196	Secreted protein, acidic and rich in cysteine (SPARC) expression in astrocytic tumour cells negatively correlates with proliferation, while vascular SPARC expression is associated with patient survival. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 183-197.	3.2	16
197	Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. <i>Cancers</i> , 2019, 11, 1072.	3.7	16
198	Malignant transformation and genetic alterations are uncoupled in early colorectal cancer progression. <i>BMC Biology</i> , 2020, 18, 116.	3.8	16

#	ARTICLE	IF	CITATIONS
199	TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. <i>Acta Neuropathologica</i> , 2021, 141, 959-970.	7.7	16
200	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069.	7.7	16
201	SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature. <i>Child's Nervous System</i> , 2016, 32, 2439-2446.	1.1	15
202	The evolution of the anaplastic cerebellar liponeurocytoma: case report and review of the literature. , 2015, 34, 19-25.		15
203	Primary anaplastic ganglioglioma with a small-cell glioblastoma component. , 2008, 27, 91-95.		15
204	Multiple thromboembolic events in fetofetal transfusion syndrome in triplets contributing to the understanding of pathogenesis of hydranencephaly in combination with polymicrogyria. <i>Human Pathology</i> , 2006, 37, 1503-1507.	2.0	14
205	Defective p53 antiangiogenic signaling in glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 894-907.	1.2	14
206	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. <i>Brain Pathology</i> , 2016, 26, 506-516.	4.1	14
207	Differential microglial regulation in the human spinal cord under normal and pathological conditions. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 650-661.	3.2	13
208	IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. <i>Haematologica</i> , 2010, 95, 1797-1798.	3.5	13
209	Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. <i>Histopathology</i> , 2011, 58, 1167-1172.	2.9	13
210	Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 122, 651-652.	7.7	13
211	Anti-tissue factor ($\text{TF}\alpha$) treatment reduces tumor cell invasiveness in a novel migratory glioma model. <i>Neuropathology</i> , 2013, 33, 515-525.	1.2	13
212	Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 655-664.	1.7	13
213	Preoperative assessment of haemostasis in patients undergoing stereotactic brain biopsy. <i>Journal of Clinical Neuroscience</i> , 2018, 53, 112-116.	1.5	13
214	Disseminating anaplastic brainstem oligodendroglioma associated with allelic loss in the tumor suppressor candidate region D19S246 of chromosome 19 mimicking an inflammatory central nervous system disease in a 9-year-old boy. <i>Human Pathology</i> , 2005, 36, 854-857.	2.0	12
215	No Evidence for BRAF-V600E Mutations in Gastroesophageal Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 426-430.	1.2	12
216	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017, 133, 325-327.	7.7	12

#	ARTICLE	IF	CITATIONS
217	Accurate calling of <i>KIAA1549</i> – <i>BRAF</i> fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 406-414.	3.2	12
218	Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. <i>Journal of Pathology</i> , 2022, 256, 61-70.	4.5	12
219	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. <i>Acta Neuropathologica</i> , 2021, 142, 873-886.	7.7	12
220	Clinical neuropathology practice news 2-2012: BRAF V600E testing. , 2012, 31, 64-66.		12
221	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5.	5.2	12
222	DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors. <i>Genome Medicine</i> , 2022, 14, 24.	8.2	12
223	Differential Expression of the Tumor Suppressor A-Kinase Anchor Protein 12 in Human Diffuse and Pilocytic Astrocytomas Is Regulated by Promoter Methylation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 933-941.	1.7	11
224	MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. <i>Archives of Dermatological Research</i> , 2014, 306, 873-884.	1.9	11
225	Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux. <i>Oncotarget</i> , 2017, 8, 67567-67591.	1.8	11
226	<i>CASP9</i> germline mutation in a family with multiple brain tumors. <i>Brain Pathology</i> , 2018, 28, 94-102.	4.1	11
227	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Children's Oncology Group ACNS0332 Trial. <i>American Journal of Neuroradiology</i> , 2019, 40, 1796-1803.	2.4	11
228	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. <i>Neuro-Oncology</i> , 2022, 24, 1689-1699.	1.2	11
229	Intramedullary Solitary Fibrous Tumor—A Benign Form of Hemangiopericytoma? Case Report and Review of the Literature. <i>World Neurosurgery</i> , 2015, 84, 189.e7-189.e12.	1.3	10
230	Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report. <i>Frontiers in Neurology</i> , 2018, 9, 398.	2.4	10
231	Reflection of neuroblastoma intratumor heterogeneity in the new OHC–NB1 disease model. <i>International Journal of Cancer</i> , 2020, 146, 1031-1041.	5.1	9
232	The embryonic stem cell factor UTF1 serves as a reliable diagnostic marker for germinomas. <i>Pathology</i> , 2014, 46, 225-229.	0.6	8
233	Spinal metastasis of gliosarcoma: Array-based comparative genomic hybridization for confirmation of metastatic spread. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1945-1950.	1.5	8
234	The case for DNA methylation based molecular profiling to improve diagnostic accuracy for central nervous system embryonal tumors (not otherwise specified) in adults. <i>Journal of Clinical Neuroscience</i> , 2018, 47, 163-167.	1.5	8

#	ARTICLE	IF	CITATIONS
235	Satisfying your neuro-oncologist: a fast approach to routine molecular glioma diagnostics. <i>Neuro-Oncology</i> , 2018, 20, 1682-1683.	1.2	8
236	High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. <i>Pathology Research and Practice</i> , 2020, 216, 152728.	2.3	8
237	Pericytes/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma. <i>Oncotarget</i> , 2018, 9, 24041-24053.	1.8	8
238	Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 351-353.	1.2	7
239	Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 382-388.	1.2	7
240	Tumour necrosis factor receptor superfamily member 9 (<sc>TNFRSF</sc>9) is upâ€regulated in reactive astrocytes in human gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, e56-67.	3.2	7
241	Genome-wide DNA methylation profiles distinguish silent from non-silent ACTH adenomas. <i>Acta Neuropathologica</i> , 2020, 140, 95-97.	7.7	7
242	Genetic and epigenetic characterization of posterior pituitary tumors. <i>Acta Neuropathologica</i> , 2021, 142, 1025-1043.	7.7	7
243	FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma. <i>Neuro-Oncology Practice</i> , 2021, 8, 209-221.	1.6	7
244	New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X. <i>Scientific Reports</i> , 2019, 9, 9973.	3.3	6
245	Mutation specific antibodies: tool or dinosaur?. <i>Oncotarget</i> , 2012, 3, 907-908.	1.8	6
246	Coincidence of Semilobar Holoprosencephaly and Chiari II Malformation: Correlation of Prenatal Diagnostics and Neuropathologic Findings. <i>Journal of Child Neurology</i> , 2006, 21, 426-429.	1.4	5
247	Lowâ€grade diffusely infiltrative tumour (LGDIT), SMARCB1â€mutant: A clinical and histopathological distinct entity showing epigenetic similarity with ATRTâ€MYC. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	5
248	NEXT-GENERATION NEUROPATHOLOGY - IMPROVING DIAGNOSTIC ACCURACY FOR BRAIN TUMORS USING DNA METHYLATION ARRAY-BASED MOLECULAR PROFILING. <i>Neuro-Oncology</i> , 2014, 16, iii4-iii4.	1.2	4
249	Glial papillary tumour of the spinal cord with <sc>SMARCB</sc>1/<sc>INI</sc>1â€loss and favourable longâ€term outcome. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 229-232.	3.2	3
250	Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model. <i>BMC Cancer</i> , 2020, 20, 427.	2.6	3
251	DNA methylation-based machine learning classification distinguishes pleural mesothelioma from chronic pleuritis, pleural carcinosis, and pleomorphic lung carcinomas. <i>Lung Cancer</i> , 2022, 170, 105-113.	2.0	3
252	SPONTANEOUS IMMUNE RESPONSES IN GBM PATIENTS AFTER COMPLETE TUMOR RESECTION ARE ASSOCIATED WITH AN IMPROVED SURVIVAL. <i>Neuro-Oncology</i> , 2014, 16, iii42-iii42.	1.2	2

#	ARTICLE	IF	CITATIONS
253	Molecular characterisation of sporadic endolymphatic sac tumours and comparison to von Hippel-Lindau disease-related tumours. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 756-767.	3.2	2
254	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. <i>Clinical Epigenetics</i> , 2021, 13, 184.	4.1	2
255	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. <i>Neuro-Oncology</i> , 2018, 20, i144-i145.	1.2	1
256	RBTT-06. TESSA JOWELL BRAIN MATRIX STUDY: A BRITISH FEASIBILITY STUDY OF MOLECULAR STRATIFICATION AND TARGETED THERAPY TO OPTIMIZE THE CLINICAL MANAGEMENT OF PATIENTS WITH GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi219-vi220.	1.2	1
257	An 8-year-Old Girl with Posterior Fossa Mass. <i>Brain Pathology</i> , 2020, 30, 713-714.	4.1	1
258	BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. <i>Blood</i> , 2012, 120, 4040-4040.	1.4	1
259	Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis. <i>Pathology Research and Practice</i> , 2022, 229, 153689.	2.3	1
260	HG-68 COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii63.2-iii63.	1.2	0
261	P08.48 Combined alterations in MAPK pathway genes, CDKN2A/B and ATRX characterize anaplastic pilocytic astrocytoma. <i>Neuro-Oncology</i> , 2016, 18, iv52-iv52.	1.2	0
262	A 49-year old female with multiple extra-axial tumors. <i>Brain Pathology</i> , 2017, 27, 235-236.	4.1	0
263	Modern Principles of CNS Tumor Classification. , 2018, , 117-129.		0
264	EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP ACNS0332 TRIAL. <i>Neuro-Oncology</i> , 2018, 20, i68-i69.	1.2	0
265	Diffuse Astrocytomas: Immunohistochemistry of MGMT Expression. , 2012, , 89-94.		0
266	Sensitivity of refractory hairy cell leukemia to BRAF inhibition.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6519-6519.	1.6	0
267	Continued Response off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. <i>Blood</i> , 2012, 120, 4600-4600.	1.4	0
268	Multicentric malignant glioma with striking morphologic heterogeneity and early and extensive metastatic spread to the bone. , 2019, 38, 261-268.		0